| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
Animal experiment: | Mice[3]NOD.H-2h4 mice are fed in the animal house until 4 weeks of age. A total of 24 male mice are then randomly separated into three different groups (n=8 per group). Mice in the control group are given sterile water without supplement. Mice in the iodine supplement (NaI) group are given 0.005% NaI in the drinking water. Mice in the NaI+Glycyrrhizic acid group are treated with 50 mg/kg Glycyrrhizic acid once daily for 4 weeks, administered via intraperitoneal injection after 8 weeks of iodine supplementation. Thyroid tissues are removed surgically under anesthesia, washed with cold saline, blotted on filter paper and weighed using an electronic balance. The thyroid gland tissues are then stored at -80℃ until use[3]. |
| 产品描述 | Glycyrrhizic acid is a triterpenoid saponinl, acting as a direct HMGB1 antagonist, with anti-tumor, anti-diabetic activities. Glycyrrhizic acid shows a series of anti-cancer-related pharmacological activities, such as broad-spectrum anti-cancer ability, resistance to the tissue toxicity caused by chemotherapy and radiation, drug absorption enhancing effects and anti-multidrug resistance (MDR) mechanisms, as a carrier material in drug delivery systems[1]. In intestinal NCI-H716 cells that secretes GLP-1, Glycyrrhizic acid promotes GLP-1 secretion with a marked elevation of calcium levels. Glycyrrhizic acid can enhance GLP-1 secretion through TGR5 activation[2]. In type 1-like diabetic rats induced by streptozotocin (STZ-treated rats), Glycyrrhizic acid increases the level of plasma GLP-1, which is blocked by triamterene at a dose sufficient to inhibit Takeda G-protein-coupled receptor 5 (TGR5)[1]. Glycyrrhizic acid (Glycyrrhizic acid; 50 mg/kg, i.p.) significantly decreases the levels of TgAb, HMGB1, TNF-α, IL-6, IL-1β in mice[3]. References: |
m.cnreagent.com